Sort
82,697 grants matching “vaccine development”
Reactions And Immunochemistry Of Carbohydrates
$799,147Pavol Kovac · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2018 · DK
Reactions And Immunochemistry Of Carbohydrates
$799,147Pavol Kovac · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2016 · DK
EpiModel 2.0: Integrated Network Models for HIV/STI Prevention Science
$799,074Samuel Jenness · Emory University · R01 · FY2018 · AI
Modulation of the early host response to SIV in pathogenic infection
$799,026Amitinder Kaur · Harvard Medical School · R01 · FY2010 · AI
Preclinical studies of a Cryptococcus vaccine for AIDS patients
$799,003Jennifer K. Lodge · Washington University · R01 · FY2021 · AI
Psychological symptoms in healthcare workers following the COVID-19 pandemic and relationship to long-term cardiovascular risk
$798,824Ari Shechter · Columbia University Health Sciences · R01 · FY2022 · HL
The yellow fever vaccine saga: Defining the viral and host determinants responsible for success versus failure
$798,777Charles M. Rice · Rockefeller University · R01 · FY2017 · AI
Vaccine Synergy through Synchronous Delivery
$798,766Michael A Barry · Mayo Clinic Rochester · R01 · FY2019 · AI
Influence of maternal virome and HIV status on infant gut virome, growth and immunity
$798,741Heather Beryl Jaspan · Seattle Children'S Hospital · R01 · FY2023 · HD
Phase II Trial of H7N9 Influenza Vaccines - VTEU
$798,690Emmanuel B Walter · Duke University · N01 · FY2014 · AI
Developmental Core
$798,612Gwendolyn B. Scott · University Of Miami School Of Medicine · P30 · FY2022 · AI
Cervicovaginal microbiome, mucosal immunity, and pathogen factors that contribute to spontaneous clearance of Chlamydia trachomatis
$798,536Rebecca M. Brotman · University Of Maryland Baltimore · R01 · FY2022 · AI
Developing broad-spectrum therapeutics against C. difficile toxins
$798,535Rongsheng Jin · University Of California-Irvine · R01 · FY2021 · AI
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinic
$798,527Monica Gandhi · University Of California, San Francisco · R01 · FY2023 · AI
A cross protective multivalent vaccine for Shigella and ETEC
$798,505David A Sack · Johns Hopkins University · R01 · FY2023 · AI
CD4 T cell-targeted nanoparticle in vivo delivery of CRISPR/Cas9 genome editors for HIV cure
$798,459Wenhui Hu · Temple Univ Of The Commonwealth · R01 · FY2019 · AI
Human Monoclonal Antibodies for Encephalitic Alphaviruses
$798,435James E Crowe · Vanderbilt University Medical Center · R01 · FY2024 · AI
Prophylactic oral vaccination for SIV and SHIV infections and AIDS prevention
$798,424Anna Aldovini · Boston Children'S Hospital · R01 · FY2019 · DE
Circularization of RNA to improve the durability of the vaccine immune response
$798,400Robert Koehler Abbott · University Of Texas Med Br Galveston · R01 · FY2025 · AI
Discovery of novel broad-spectrum coronavirus inhibitors
$798,337Vineet D Menachery · University Of Texas Med Br Galveston · U19 · FY2023 · AI
Molecular determinants of anti-RBC alloantibody evanescence
$798,296Chance Marion John Luckey · University Of Virginia · R56 · FY2022 · HL
Prospective annual estimates of influenza vaccine effectiveness and burden of disease
$798,289Michael L Jackson · Kaiser Foundation Research Institute · U01 · FY2017 · IP
Prospective annual estimates of influenza vaccine effectiveness and burden of disease
$798,289Michael L Jackson · Kaiser Foundation Health Plan Of Washington · U01 · FY2016 · IP
TASK A04: EVALUATION OF THERAPEUTICS AND VACCINES IN MOUSE MODELS OF DENGUE VIRUS
$798,251David Beasley · University Of Texas Med Br Galveston · N01 · FY2020 · AI
Development of novel multivalent mucosal vaccines for human noroviruses
$798,173Jianrong Li · Ohio State University · R01 · FY2025 · AI